Research programme: immunotherapeutics - Rheos Medicines/Roche
Latest Information Update: 28 Jan 2024
At a glance
- Originator Rheos Medicines
- Developer Rheos Medicines; Roche
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Jan 2024 No recent reports of development identified for research development in Inflammation in USA
- 19 Dec 2019 Rheos Medicines and Roche collaborate to develop immunotherapeutics for Autoimmune disorders and Inflammation